To date, results from structural and functional assays by several multicenter trials suggested that IDH1 R132, which resides at the active site of enzyme substrate affinity, promotes oncogenesis in both glioma and AML [9,11,20,33]. This evidence concerns the gene IDH1 and central nervous system cancer.